医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Starpharma: Commencement of Phase 1 Trial for AZD0466 Utilising DEP® Delivery Technology

2019年12月30日 AM08:07
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that AstraZeneca (LSE/STO/NYSE:AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP® Bcl2/xL conjugate) and the first patient has been successfully dosed. The trial will recruit patients with a range of cancers and will be conducted at 4-5 US sites.

The development of AZD0466, is being progressed under a multi-product license whereby Starpharma is eligible to receive development, launch and sales milestones of up to US$124 million, plus tiered royalties on net sales. The first dose of AZD0466 administered in the phase 1 trial has triggered a milestone payment to Starpharma of US$3 million. AstraZeneca also funds the development costs of DEP® AstraZeneca products under the license.

AstraZeneca describes AZD0466 as having the potential to be a ‘best-in-class’ agent in this field with a broad opportunity in solid and haematological tumours (blood cancers) due to its ability to target both Bcl2 and Bcl/xL1.

Bcl2 is a clinically validated oncology target with the Bcl2 inhibitor, venetoclax (Venclexta™ – AbbVie/Genentech), being approved by the US FDA in 2016 with estimated peak global sales projected to be between US$2-3 billion2.

Dr Jackie Fairley, Starpharma CEO, commented: “It is really exciting to achieve this important milestone both for our collaboration with AstraZeneca and for Starpharma’s DEP® platform. This is our first partnered DEP® product to enter the clinic, alongside our three internal DEP® products, DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan. AZD0466 is a great illustration of the benefits that can be created for novel agents using Starpharma’s DEP® platform and we look forward to further updates as the trial progresses.”

About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

1 3rd AstraZeneca-MedImmune-CRUK Cambridge Centre Symposium 2017 presentation
2 https://www.fiercepharma.com/pharma/abbvie-roche-drive-venclexta-toward-3b-rituxan-combo-nod-cll

View source version on businesswire.com: https://www.businesswire.com/news/home/20191229005009/en/

CONTACT

Media

WE Worldwide

Rebecca Wilson

+61 417 382 391

rwilson@we-worldwide.com

Arthur Chan

+61 2 9237 2805

arhurc@we-worldwide.com

Starpharma

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024